Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2026 January
  • Home
  • Archive for January, 2026
Watsnex Podcast
user

Host: Pascal Côté linkedin-img

user

Guest: Ross Youngs linkedin-img


×

AI, Microbiomes, & 8 Orders of Magnitude Improvement

  • January 29 2026
  • Video - Date: 01/26/2026
  • Length: 25:34 min

AI, Microbiomes, & 8 Orders of Magnitude Improvement

Summary – I recently sat down with Pascal Côté on the WATSNEX Podcast to discuss “AI, Microbiomes, and 8 Orders of Magnitude Improvement.” We dove deep into how industrial-scale microbiome mining and data depth are transforming biotech manufacturing and drug discovery. This conversation is part of the WATSNEX Podcast Founding Series, featuring leaders in biopharma and medtech. Watch the full episode here: https://youtu.be/16dg9QKOEcM

Reel1: https://youtube.com/shorts/tHsW1XkqEuw?feature=share

Reel2: https://youtube.com/shorts/AQhGTWx94EU?feature=share

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo

  • January 27 2026

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo (Jan 27, 2026) by Reuters. BERLIN, Jan 27 (Reuters) – Roche’s experimental obesity drug, which works in a similar way to Eli Lilly’s Zepbound, produced as much as 22.5% weight loss in a mid-stage trial, underpinning the Swiss drugmaker’s efforts to catch up with

Continue Reading

RSS Industry News

  • Convergent extreme reductive evolution in ancient planthopper symbioses February 7 2026
  • Microbiota-derived IPA protects against colitis by regulating intestinal HMGCS2-mediated ketogenesis to facilitate mucosal healing February 6 2026
  • Host factors dictate gut microbiome alterations in chronic kidney disease more strongly than kidney function February 5 2026
  • Mg2+ in drinking water boosts Salmonella infection risk by rewiring gut ecology and virulence February 4 2026
  • Prucalopride, a serotonin type 4 receptor agonist, induces fast anxiolytic/antidepressant effects and concomitant changes in the gut microbiota February 4 2026
  • What my cave stay taught me about sensors February 4 2026
  • The Nugent score is an inappropriate diagnostic tool for neovaginal bacteria in transfeminine people February 3 2026
  • Gut microbiota-derived butyrate primes systemic immunity in honey bees by mediating lipid metabolic reprogramming February 2 2026
  • Gut microbial signatures expose the westernized lifestyle of urban Ethiopian children January 31 2026
  • Simiao Decoction alleviates hyperuricemia-induced renal injury through regulating gut dysbiosis and decreasing gut-derived uremic toxins January 31 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • AI, Microbiomes, & 8 Orders of Magnitude Improvement
  • Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo
  • The Billion Dollar Savings per Approved Drug
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.